Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C By Watertime - August 18, 2026 0 Post Content RELATED ARTICLESMORE FROM AUTHOR Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study Why Perimenopause Belongs in Psychedelic Research
